We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.44B
AUM Growth
-$537M
Cap. Flow
+$101M
Cap. Flow %
2.93%
Top 10 Hldgs %
35%
Holding
141
New
7
Increased
68
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$42.4M
2
PEN icon
Penumbra
PEN
+$31.3M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$26.2M
4
HUM icon
Humana
HUM
+$25.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$94M
2
EHC icon
Encompass Health
EHC
+$35.7M
3
IRTC icon
iRhythm Holdings
IRTC
+$22M
4
XENT
Intersect ENT, Inc
XENT
+$15.4M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Consumer Staples 0.96%
3 Industrials 0.47%
4 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMDA
101
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.85M 0.11%
2,175,000
+20,700
+1% +$52.6K
PRTK
102
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.35M 0.1%
1,734,037
+7,400
+0.4% +$16.1K
BLSA
103
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.06M 0.09%
309,000
– –
OKUR
104
OnKure Therapeutics
OKUR
$164M
$3.03M 0.09%
114,319
– –
SPRB
105
Spruce Biosciences
SPRB
$127M
$2.82M 0.08%
21,636
– –
MGNX icon
106
MacroGenics
MGNX
$259M
$2.82M 0.08%
954,728
+22,000
+2% +$116K
FATE icon
107
Fate Therapeutics
FATE
$322M
$2.73M 0.08%
110,000
– –
THRX
108
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.42M 0.07%
437,329
– –
CGEN icon
109
Compugen
CGEN
$221M
$2.39M 0.07%
1,289,990
– –
JYAC
110
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.04M 0.06%
206,200
– –
FUSN
111
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.02M 0.06%
809,854
-138,473
-15% -$636K
PRLD icon
112
Prelude Therapeutics
PRLD
$385M
$1.93M 0.06%
368,959
– –
FULC icon
113
Fulcrum Therapeutics
FULC
$286M
$1.88M 0.05%
384,590
-50,000
-12% -$489K
TPST icon
114
Tempest Therapeutics
TPST
$16.6M
$1.77M 0.05%
63,358
– –
PHAS
115
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.67M 0.05%
2,774,869
+161,044
+6% +$154K
EPIX
116
DELISTED
ESSA Pharma
EPIX
$1.65M 0.05%
524,944
– –
SYRE icon
117
Spyre Therapeutics
SYRE
$9.29B
$1.55M 0.05%
122,881
+50,424
+70% +$1.77M
TLPH icon
118
Talphera
TLPH
$73.2M
$1.55M 0.05%
316,460
– –
VIGL
119
DELISTED
Vigil Neuroscience
VIGL
$1.22M 0.04%
471,958
– –
VINC
120
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.07M 0.03%
40,710
– –
ELVN icon
121
Enliven Therapeutics
ELVN
$4.35B
$1.03M 0.03%
210,601
– –
BCEL
122
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$828K 0.02%
462,530
– –
APLT
123
DELISTED
Applied Therapeutics
APLT
$665K 0.02%
701,680
– –
SPRO icon
124
Spero Therapeutics
SPRO
$71.2M
$571K 0.02%
770,710
-220,203
-22% -$640K
NUVB.WS
125
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$38K ﹤0.01%
134,028
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rock Springs Capital Management held 141 positions worth $3.44B, down 14% from $3.97B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q2 2022 filing shows 7 new, 68 increased, 12 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M. The largest sale was HCA Healthcare, an estimated $94M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q2 2022 buy was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M.
  • Rock Springs Capital Management added most to Align Technology in Q2 2022, an estimated $42.4M increase.
  • Rock Springs Capital Management's biggest Q2 2022 reduction was iRhythm Holdings, cutting an estimated $22M.
  • Rock Springs Capital Management fully exited HCA Healthcare in Q2 2022, selling an estimated $94M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.44B portfolio in Q2 2022.
  • Rock Springs Capital Management opened 7 new positions and closed 10 in Q2 2022.
  • Rock Springs Capital Management's portfolio value fell 14% quarter-over-quarter to $3.44B.

Based on Rock Springs Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.